Milena Weinstein, MD
Urogynecology and Reconstructive Pelvic Surgery · Boston, MANPI 1255489753
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Boston Scientific at 52.4% of the total. 2025 is the largest year on record at $1,002, 5.5 times the $181 reported in 2019.
Across 31 payments — averaging $114.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Axonics, Inc.$764
- Medtronic$409
- C. R. Bard, Inc. & Subsidiaries$272
- Caldera Medical, Inc$185
- Coloplast$57
Across 5 payments — averaging $10,472 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Renovia Inc$52K
What the payments were for
- Consulting fees$2728%
- Food & beverage$3,21891%
- Education$572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $1,860 |
| Axonics, Inc. | 6 | $764 |
| Medtronic(2 entities) | 4 | $409 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $272 |
| Caldera Medical, Inc | 1 | $185 |
| Coloplast | 2 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bulkamid$635
- UPSYLON$396
- Axonics$396
- Advantage System$324
- INTERSTIM$282
- Solyx SIS System$268
- GENERAL FEMALE SUI$223
- Desara$185
- SOLYX$123
How this compares
$3,547 in reported general payments places this provider in the 55th percentile of 35 urogynecology and reconstructive pelvic surgery providers in Massachusetts.
See all urogynecology and reconstructive pelvic surgery providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 30 | $34,346 |
| Estradiol | 163 | $19,277 |
| MyrbetriqMirabegron | 15 | $12,498 |
| YuvafemEstradiol | 46 | $9,465 |
| Methenamine Hippurate | 29 | $2,195 |
| Ibuprofen | 31 | $95 |
| Oxycodone Hcl | 27 | $52 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $26 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Boston
- Lori JonesBoston$22K
- John Al JamalBoston$15K
- Youngwu KimBoston$14K
- Tsung MouBoston$10K
- Evelyn HallBoston$6K
- Roger LefevreBoston$5K
- May WakamatsuBoston$4K
- Edward KimBoston$3K
- Mallika AnandBoston$443
- Gnankang NapoeBoston$28
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.